Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00141960
Status:
COMPLETED
Last Update Posted:
2011-11-21
First Post:
2005-09-01
Brief Title:
Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
YM1170 Phase 23 Study A Double Blind Placebo Controlled Group-comparison Study in Patients With Non-erosive Gastroesophageal Reflux Disease
Status:
COMPLETED
Status Verified Date:
2010-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Gastroesophageal reflux disease GERD considered to be associated with mucosal damages in the esophagus and heartburn which may sometimes interfere with daily activities due likely to reflux of acid gastric contents While most of the patients given the diagnosis of GERD do not exhibit endoscopically obvious impairment in esophageal mucous membrane they have subjective symptoms of non-erosive GERD including heartburn But no drug has been launched in Japan which targets non-erosive GERD This study will examine the efficacy and safety of famotidine in subjects with non-erosive GERD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None